Abbott Laboratories Reports Revenue Growth but Stock Slips on Guidance Cut
Abbott Laboratories (ABT) reported an 8% year-over-year revenue increase to $11.2 billion in Q1 2026, surpassing expectations, driven by a 13% growth in its MedTech division. However, the stock declined following a guidance cut, marking the company's first revenue beat in two quarters.
Tickers: $ABT
Topics: Abbott Laboratories Earnings MedTech Division Revenue Growth